Lumos Pharma Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Lumos Pharma wird ein Gewinn- und Umsatzwachstum von 50.1% bzw. 58.2% pro Jahr prognostiziert, während der Gewinn pro Aktie um 66% pro Jahr wachsen soll.

Wichtige Informationen

50.1%

Wachstumsrate der Gewinne

66.0%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.5%
Wachstumsrate der Einnahmen	58.2%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	16 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Here's Why We're Not Too Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Situation

Mar 22

Companies Like Lumos Pharma (NASDAQ:LUMO) Are In A Position To Invest In Growth

Nov 04

What Kind Of Investors Own Most Of Lumos Pharma, Inc. (NASDAQ:LUMO)?

Dec 09

Lumos Pharma (LUMO) Investor Presentation - Slideshow

Nov 17

Lumos Pharma, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 11

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:LUMO - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	28	-24	-44	N/A	4
12/31/2025	9	-40	-43	N/A	5
12/31/2024	1	-41	-42	N/A	2
3/31/2024	2	-37	-35	-35	N/A
12/31/2023	2	-34	-31	-31	N/A
9/30/2023	2	-33	-30	-30	N/A
6/30/2023	2	-32	-27	-27	N/A
3/31/2023	2	-31	-28	-28	N/A
12/31/2022	2	-31	-27	-27	N/A
9/30/2022	1	-28	-27	-27	N/A
6/30/2022	1	-29	-28	-28	N/A
3/31/2022	0	-30	-27	-27	N/A
12/31/2021	0	-30	-30	-30	N/A
9/30/2021	0	-27	-31	-31	N/A
6/30/2021	0	-18	-23	-23	N/A
3/31/2021	0	-15	-30	-30	N/A
12/31/2020	0	-6	-23	-23	N/A
9/30/2020	0	-7	-19	-19	N/A
6/30/2020	0	-12	-21	-21	N/A
3/31/2020	0	-10	-10	-10	N/A
12/31/2019	N/A	-13	-9	-9	N/A
9/30/2019	N/A	-11	-8	-8	N/A
12/31/2018	N/A	-11	-11	-7	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: LUMO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: LUMO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: LUMO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: LUMODie Einnahmen des Unternehmens (55.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.4% pro Jahr).

Hohe Wachstumseinnahmen: LUMODie Einnahmen des Unternehmens (55.1% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von LUMO in 3 Jahren voraussichtlich hoch sein wird

Lumos Pharma Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 11%

Price target increased by 15% to US$23.33

Consensus revenue estimates decrease by 20%, EPS upgraded

Price target increased by 13% to US$20.25

Consensus revenue estimates increase by 43%, EPS downgraded

Consensus revenue estimates increase by 99%

Recent updates

Lumos Pharma, Inc. Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024

We're A Little Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Rate

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 11%

Lumos Pharma, Inc. to Report Q1, 2024 Results on May 15, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 15% to US$23.33

Lumos Pharma, Inc. to Report Fiscal Year 2023 Results on Mar 07, 2024

Lumos Pharma, Inc. Promotes Pisit Pitukcheewanont to Chief Medical Officer

Consensus revenue estimates decrease by 20%, EPS upgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Lumos Pharma Announces New Data and Analysis of 15 Subjects from Oragrowth212 Trial Presented At the 2023 ESPE Annual Meeting

Lumos Pharma, Inc. Announces Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual Meeting

Price target increased by 13% to US$20.25

We're Keeping An Eye On Lumos Pharma's (NASDAQ:LUMO) Cash Burn Rate

First quarter 2023 earnings released: US$0.89 loss per share (vs US$0.92 loss in 1Q 2022)

Consensus revenue estimates increase by 43%, EPS downgraded

Lumos Pharma, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Lumos Pharma, Inc. Announces Departure of David B. Karpf, Chief Medical Officer, Effective June 29, 2023

Lumos to Highlight New LUM-201 Data and Analysis Presented at ENDO 2023 in Virtual KOL Webinar

New minor risk - Share price stability

Insider recently sold US$611k worth of stock

Insider recently bought US$455k worth of stock

Lumos Pharma, Inc. Announces Encouraging Data from Lumos Pharma OraGrowtH Trials Presented at Annual Pediatric Endocrine Society Meeting (PES)

Consensus revenue estimates increase by 99%

Is Lumos Pharma (NASDAQ:LUMO) In A Good Position To Deliver On Growth Plans?

Consensus EPS estimates fall by 17%

Lumos Pharma, Inc. to Report Fiscal Year 2022 Results on Mar 01, 2023

Consensus revenue estimates increase by 66%

Price target decreased to US$21.83

Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral Lum-201 for Moderate Pediatric Growth Hormone Deficiency

Lumos Pharma, Inc. (NasdaqGM:LUMO) announces an Equity Buyback for $3 million worth of its shares.

Lumos Pharma announces new buyback program

Lumos Pharma, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Consensus forecasts updated

Lumos Pharma, Inc. Announces Clinical Development Updates

Price target decreased to US$25.00

Lumos Pharma, Inc. Reaches 50% Randomization Milestone in Phase 2 Oragrowth210 Trial Evaluating Oral Lum-201 in Pghd

Here's Why We're Not Too Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Situation

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$25.00

Lumos Pharma, Inc. to Report Fiscal Year 2021 Results on Mar 10, 2022

Third quarter 2021 earnings released: US$0.90 loss per share (vs US$0.21 profit in 3Q 2020)

Companies Like Lumos Pharma (NASDAQ:LUMO) Are In A Position To Invest In Growth

Independent Director recently bought US$56k worth of stock

First half 2021 earnings released: US$2.08 loss per share (vs US$1.08 loss in 1H 2020)

Price target decreased to US$27.67

Lumos Pharma, Inc. Announces New Data Highlights from Three Patients with Pediatric Growth Hormone Deficiency

Chief Medical Officer has left the company

Lumos Pharma, Inc. Announces Results of Peer-Reviewed Analyses of Data from Two Prior Pediatric Growth Hormone Deficiency

New 90-day low: US$14.97

Independent Director has left the company

Lumos Pharma, Inc. to Report Fiscal Year 2020 Results on Mar 09, 2021

Lumos Pharma, Inc. Announces Board Changes

Lumos Pharma, Inc. Announces Resignation of Eugene P. Kennedy as Chief Medical Officer, Effective March 6, 2021

New 90-day high: US$17.47

What Kind Of Investors Own Most Of Lumos Pharma, Inc. (NASDAQ:LUMO)?

New 90-day high: US$15.80

Lumos Pharma (LUMO) Investor Presentation - Slideshow

Analysts increase revenue estimates to US$60.7k

Lumos Pharma, Inc. 2020 Q3 - Results - Earnings Call Presentation

Lumos Pharma, Inc. to Report Q3, 2020 Results on Nov 10, 2020

Analysts lower revenue estimates to US$2.65m

Lumos Pharma, Inc. to Report Q2, 2020 Results on Aug 13, 2020

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken